Aytu BioPharma(AYTU)
搜索文档
Aytu BioPharma(AYTU) - 2021 Q3 - Earnings Call Transcript
2021-05-18 08:24
Aytu Biopharma, Inc. (NASDAQ:AYTU) Q3 2021 Earnings Conference Call May 17, 2021 4:30 PM ET Company Participants Joshua Disbrow - Chairman and CEO Richard Eisenstadt - CFO Conference Call Participants Jennifer Kim - Cantor Fitzgerald Operator Good afternoon and thank you for joining us today for the Aytu Biopharma Financial Results and Business Update Call for the Fiscal Third Quarter Ended March 31st, 2021. With me this afternoon are Aytu's Chairman and Chief Executive Officer, Josh Disbrow; and Chief Fina ...
Aytu BioPharma(AYTU) - 2021 Q2 - Earnings Call Transcript
2021-02-12 18:43
Aytu BioScience, Inc. (NASDAQ:AYTU) Q2 2021 Earnings Conference Call February 11, 2021 4:30 PM ET Company Participants Joshua Disbrow - Chairman & CEO David Green - CFO, Secretary & Treasurer Conference Call Participants Vernon Bernardino - H.C. Wainwright & Co. Operator Good afternoon, and thank you for joining us for the Aytu BioScience Second Quarter Fiscal 2021 Business Update Call for the Quarter Ended December 31, 2020. With me this afternoon are Aytu's Chairman and Chief Executive Officer, Josh Disbr ...
Aytu BioPharma(AYTU) - 2021 Q1 - Quarterly Report
2020-11-13 05:32
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38247 AYTU BIOSCIENCE, INC. (www.aytubio.com) Delaware 47-0883144 (State or other jurisdiction of incorporation or organization) (IRS Emp ...
Aytu BioPharma(AYTU) - 2020 Q4 - Annual Report
2020-10-07 04:13
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 333-146542 AYTU BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) 47-0883144 | --- | --- | |---------------------------|------------------------------------ ...
Aytu BioPharma(AYTU) - 2020 Q3 - Earnings Call Transcript
2020-05-15 08:34
Aytu BioScience, Inc. (NASDAQ:AYTU) Q3 2020 Results Earnings Conference Call May 14, 2020 4:30 PM ET Company Participants Joshua Disbrow - Chairman & CEO David Green - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Good afternoon, and thank you for joining us at the Aytu BioScience Third Quarter Fiscal 2020 Business Update Call for the quarter ending March 31, 2020. With me this afternoon are Aytu's Chairman and Chief Executive Officer, Josh Disbrow; and Chief Financial Officer ...
Aytu BioPharma(AYTU) - 2020 Q3 - Quarterly Report
2020-05-15 06:55
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share AYTU The NASDAQ Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...
Aytu BioPharma(AYTU) - 2020 Q2 - Quarterly Report
2020-02-15 05:55
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share AYTU The NASDAQ Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss ...